Tofacitinib
Thông số
477600-75-2Số CAS
689-145-4Số EC
3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrileTên IUPAC
C16H20N6OCông thức hóa học
312.37 g/molKhối lượng phân tử
Tofacitinib; 477600-75-2; Tasocitinib; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; Cp-690 free base; tofacitinibum; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; CP690550; 87LA6FU830; CP-690550 FREE BASE; CP-690,550 FREE BASE; CP690,550; CP-690-550; CHEBI:71200; DTXSID90197271; CP-690; 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-; 3-((3R,4R)-4-methyl-3-(methyl((7H-pyrrolo(2,3-d)pyrimidin-4-yl))amino)piperidin-1-yl)-3-oxopropanenitrile; RefChem:6313; JAK inhibitors: tofacitinib; DTXCID00119762; L04AA29; 689-145-4; 1259404-17-5; Tofacitinib (CP-690550,Tasocitinib); 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; rac-Tofacitinib; Tofacitinib (CP-690550); Tofacitinib [USAN]; C16H20N6O; CHEMBL221959; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-; racemic-tofacitinib; racemic-Tasocitinib; MFCD22628813; Tofacitinib (USAN); MFCD11035919; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxo-propanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (+)-TOFACITINIB; Tofacitinib [USAN:INN]; UNII-87LA6FU830; Tofacitinib?; Tofacitinib Base; 3eyg; 3fup; 3lxk; 4oti; (Rac)-Tofacitinib; 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-.BETA.-OXO-, (3R,4R)-; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-.beta.-oxo-, (3R,4R)-; 3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; MI1; 477600-75-2 (free base); Tofacitinib (Standard); TOFACITINIB [MI]; TOFACITINIB [INN]; TOFACITINIB [VANDF]; PFE-PKIS 25; PFE-PKIS_25; TOFACITINIB [WHO-DD]; SCHEMBL322753; GTPL5677; orb1224990; orb1300872; SCHEMBL29351183; HSDB 8311; EX-A205; UJLAWZDWDVHWOW-YPMHNXCESA-N; GLXC-90307; BDBM50193995; EBC-11351; HY-40354R; NSC782351; NSC800953; AKOS005145814; AKOS005258733; AC-8193; AT43433; CCG-264998; CS-0050; DB08895; FT32555; GS-6106; NSC-782351; NSC-800953; SDCCGSBI-0654407.P002; TOFACITINIB (CONTROLLED RELEASE); NCGC00229511-02; NCGC00229511-04; NCGC00229511-10; NCGC00229511-24; NCGC00229511-25; NCGC00244463-01; 3-[(3R*,4R*)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; HY-40354; NS00069315; T6321; CP- 690 550; D09970; AB01565786_02; EN300-1718468; AR-270/43507983; F050788; Q3530324; BRD-K31283835-001-01-9; BRD-K31283835-048-04-4; (3R,4R)-3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine-propanenitrile; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-|A-oxo-, (3R,4R)-; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile citrate; 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]piperidin-1-yl}-3-oxo-propionitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; 3-{4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile; REL-3-((3R,4R)-4-METHYL-3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO)PIPERIDIN-1-YL)-3-OXOPROPANENITRILETên gọi khác
Sản phẩm chứa Tofacitinib
잭파즈정10밀리그램(토파시티닙)토파시아정(토파시티닙)잭파즈정5밀리그램(토파시티닙)지에케이정5밀리그램(토파시티닙)토시닙정5밀리그램(토파시티닙)엘란즈정5밀리그램(토파시티닙)젤즈원정5밀리그램(토파시티닙)TofacitinibTOFACITINIB (CP-690550,TASOCITINIB)TofacitinibTofacitinibTofacitinib
Trang 1/2
Công ty đang bán Tofacitinib
한림
한림제약(주)Republic of Korea일양
일양약품(주)Republic of Korea유니
유니메드제약(주)Republic of KoreaHC
Hangzhou Celor Chemical Co.,Ltd.ChinaSD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaHP
Harway Pharma CO., LTDChinaSX
Sichuan Xieli Pharmaceutical Co., Ltd.ChinaCH
Chongqing Huapont Shengchem Pharmaceutical Co., Ltd.China하나
하나제약(주)Republic of Korea(주
(주)킴스제약Republic of KoreaTrang 1/2